Impact of thyroid autoimmunity on the cumulative live birth rates after IVF/ICSI treatment cycles

Table 5 Subgroup analysis of cumulative live birth outcomes according to thyroid antibody titre

Group		No. of patients	No. of LB	CLBR (%) ^a	OR (95% CI)	Adjusted OR (95%) ^*
TGAb	High titres (≥ 141.3 IU/mL)	390	215	55.1	1	1
TGAb	Low titres (<141.3 IU/mL)	389	185	47.6	0.74 (0.56–0.98)	0.75 (0.56–1.01)
TPOAb	High titres (≥ 217.1 IU/mL)	290	144	49.7	1	1
TPOAb	Low titres (<217.1 IU/mL)	290	142	49	0.97 (0.70–1.35)	0.98 (0.69–1.39)

TGAb, thyroglobulin antibody; TPOAb, thyroid peroxidase antibody; LB, live birth; CLBR, cumulative live birth rate; OR, odds ratio
^a CLBR: cumulative live birth was defined as the delivery of one or more living infants in the first and subsequent frozen-thawed cycles. The cumulative live birth rate was calculated as the number of cumulative live births divided by the number of COS cycles
^* The multivariate model was adjusted for age, body mass index, cause of infertility, FT4, TSH, COS protocols, type of transfer (fresh vs. frozen), type of transferred embryo (cleavage-stage embryo vs. blastocyst), and fertilization method (IVF vs. ICSI)

ISSN: 1471-2393